SCHEDULE: Vestal Point Capital Discloses 7.5% Stake in Lexeo Therapeutics
Schedule 13G
Vestal Point Capital, LP and Ryan Wilder have disclosed a 7.5% beneficial ownership stake in Lexeo Therapeutics, Inc., including shares from warrants.
Summary
- Vestal Point Capital, LP and Ryan Wilder collectively beneficially own 4,117,302 shares of Lexeo Therapeutics, Inc. Common Stock.
- This ownership represents 7.5% of the company's outstanding Common Stock.
- The reported amount includes 867,302 shares of Common Stock issuable upon the exercise of warrants.
- The percentage is calculated based on 54,001,214 shares of Common Stock outstanding as of August 12, 2025, as reported in Lexeo Therapeutics' Form 10-Q for the quarter ended June 30, 2025.
- The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Lexeo Therapeutics, Inc.
Sentiment
Score: 5
Explanation: Factual disclosure of beneficial ownership, no explicit positive or negative operational or financial news.
Management Comments
- The Reporting Persons certify that, to the best of their knowledge and belief, the securities were acquired and are held in the ordinary course of business and not for the purpose or with the effect of changing or influencing the control of Lexeo Therapeutics, Inc.
Industry Context
This filing is a standard disclosure of beneficial ownership by an investment firm, providing transparency on significant holdings in a publicly traded company. It does not inherently reflect broader industry trends but rather an investment decision by a specific entity.
Related Party Transactions
- Vestal Point Capital, LP is the investment adviser to the Vestal Point Fund and Account, which directly holds the reported shares.
- Ryan Wilder is the Chief Investment Officer and Managing Partner of Vestal Point Capital, LP and the Managing Member of Vestal Point Capital, LLC, its general partner.
Stakeholder Impact
- Shareholders gain transparency regarding a significant institutional investor's stake in Lexeo Therapeutics, Inc.
Key Dates
| Date | Description |
|---|---|
| 06/30/2025 | End of the quarterly period for Lexeo Therapeutics' Form 10-Q. |
| 08/12/2025 | Date as of which 54,001,214 shares of Common Stock were outstanding, used for percentage calculation. |
| 08/14/2025 | Date Lexeo Therapeutics filed its Quarterly Report on Form 10-Q for the period ended June 30, 2025. |
| 09/30/2025 | Date of event which requires the filing of this statement (reporting period end date for beneficial ownership). |
| 11/14/2025 | Signature date of the Schedule 13G filing. |
Keywords
Lexeo Therapeutics, Vestal Point Capital, Ryan Wilder, Beneficial Ownership, Schedule 13G, Common Stock, Warrants, Investment Adviser
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.